Komori
I

IVY COSMETICS CORPORATION

4918Materials and ChemicalsMicro cap
303JPY+2.0%
★ Watch (sign-up required)
Price history
¥303Latest-57.9%
Drag across the chart to measure the move between two points.Delayed 15 minutes · monthly closing basis
Business overview

The Company is an integrated cosmetics manufacturer whose principal business is the manufacture and sale of cosmetics and quasi-drugs, with door-to-door sales as its core business. Its principal business is door-to-door cosmetics, under which it has sales agreements with 238 domestic "sales companies" and develops, manufactures and sells cosmetics, quasi-drugs, beauty supplements and cosmetic accessories, while also providing sales support to its sales organizations. Products are sold to customers through the sales companies, which are generally the Company's shipping destinations. The Company records sales at the amount shipped to the sales companies. Its product portfolio is centered on core skincare lines including Ivy Prestige, Ivy Cosmos II, Basic Plus and Re White, as well as the Ivy Attracty line, which includes cleansing products and facial cleansers. Body-care products include the Garland line, while the Shield Sun line covers sunscreens and body lotions. The Company also offers optional-care products such as facial masks and lip treatments. Special-care products centered on serums include Red Power Serum and White Power Serum, the latter being a quasi-drug. Makeup is primarily offered under the Chulier line, including foundations, lip colors, eye colors and eyeliners. Hair care is centered on the Hair Primary line, comprising shampoos, conditioners and treatments, and also includes the quasi-drug hair-growth product Medicated Scalp Care Stem Signal. Other products include the men's cosmetics line Men's One, hand creams and the home-use multifunctional beauty device Ivy Beauty Partner. Beauty supplements include foods with function claims and foods with nutrient function claims. Cosmetic accessories and related products include cosmetic tools and the paid portion of Ivy News.

Recurring subjects
No threads yetThis company's filings have not been read yet. We are adding them progressively.
Companies sharing a theme
Loading
Key numbersShowing 8 of 19
PER
11.62How many years of earnings it would take to buy the stock. The market average is generally considered to be around 15.
PBR
0.88How many times the company's net assets? Around 1x is generally considered a benchmark.
ROE
-10.7%Earning power. A figure above 10% is generally considered good.
Dividend yield
0.0%The annual dividend as a percentage of the share price.
Market capitalization
¥2.0bnShare price × number of shares. The value of the entire company.
Equity ratio
67.7%The proportion of assets funded by money that does not have to be repaid.
Operating margin
-80.7%The percentage of revenue remaining from the company’s core business.
Revenue growth (3 years)
-4.0%The average annual growth in sales over the past three years.
What to watch next
Specific measures and progress disclosures for the medium- to long-term five-year revision, “Ivy creates Japanese skin,” including a fundamental overhaul of the product portfolio and sales structure
2026 onward (plan launch)Impact HighLikelihood Medium
Core-product shipment volumes and achievement of targets, particularly quantitative confirmation that the “shipment shortfalls” for Red Power Serum and White Power Serum have been resolved
Quarterly to annual results from the next fiscal period onwardImpact HighLikelihood Medium
Expansion of exports to Taiwan, including increased local sales of Stem Signal
2026 onwardImpact MediumLikelihood Medium
Specific progress toward the commercialization or licensing of R&D and IP assets, including NRF2 activators, MAO inhibitors and TGF-β signaling inhibitors
Medium term (uncertain)Impact MediumLikelihood Low
Assessment of the accounting impact from preparations for, and the commencement of, adoption of the new lease accounting standard
Fiscal year ending March 2028Impact LowLikelihood Medium
What to watch next
Loading
Who owns itTop holders total 34.9%
Listed holders 34.9%Everyone else 65.1%
株式会社白銀社16.92%
株式会社ブリーズ3.34%
アイビー化粧品 Business Partner Shareholding Association2.42%
安藤 英基2.14%
Shirogane Emiko (白銀 恵美子)1.89%
安藤 英雄1.80%
Shirogane Koji (白銀 浩二)1.73%
アイビー共栄会1.69%
2 other listed holders2.97%
Who owns it
HolderOwnership (%)
株式会社白銀社16.92
株式会社ブリーズ3.34
アイビー化粧品 Business Partner Shareholding Association2.42
安藤 英基2.14
Shirogane Emiko (白銀 恵美子)1.89
安藤 英雄1.80
Shirogane Koji (白銀 浩二)1.73
アイビー共栄会1.69
2 other listed holders2.97
This company's documents
Timely disclosures
Threads